Technology · 19/10/2026

Full-Life Technologies Reports First-in-Human Imaging Data for c-MET-Targeting Theranostic Ligand FL-261 Showing Robust Tumor Uptake, High Lesion Contrast and No Tracer-Related Serious Adverse Events in Patients with NSCLC

Data featured as a Top Rated Oral Presentation at the 39th Annual Congress of the European Association of Nuclear Medicine First-in-human imaging performed in 10 patients with non-small cell lung cancer showed no trac…